- Free from Publisher RA Gerber, JC Cappelleri, IA Kourides, RA … - Diabetes Care, 2001 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Subjects with type 1 diabetes participated in a
12-week open-label trial and were randomized to either an inhaled insulin
regimen or a subcutaneous insulin regimen. Subjects (n = 69) were asked to ... Cited by 101 - Related articles - BL Direct - All 8 versions
JC Cappelleri, WT Cefalu, J Rosenstock, IA … - Clinical therapeutics, 2002 - Elsevier Methods: This was a 12-week randomized, open-label, parallel-group, controlled
trial in patients with type 2 diabetes. They were randomized to receive either a
subcutaneous insulin regimen (split/mixed insulin with 2 to 3 injections ... Cited by 78 - Related articles - All 5 versions
- Free from Publisher A Himmelmann, J Jendle, A Mellén, AH … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Pharmacokinetic results for evaluable subjects were derived from serum
insulin profiles. The amount of insulin absorbed during the first 6 h after
dosing (area under the exogenous serum insulin curve from 0 to 6 h [AUC ... Cited by 100 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org J Rosenstock, JC Cappelleri, B Bolinder, RA … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Of the 60 patients who received inhaled insulin during the parent
studies, 85.0% (n = 51) chose to continue treatment, 13.3% (n = 8) switched to
subcutaneous insulin, and 1.7% (n = 1) did not continue. Of the 61 patients ... Cited by 132 - Related articles - BL Direct - All 12 versions
- ►diabetesjournals.org N Freemantle, L Blonde, D Duhot, M Hompesch … - Diabetes Care, 2005 - Am Diabetes Assoc Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment
of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin
formulation is delivered by aerosol, permitting the noninvasive ... Cited by 102 - Related articles - All 7 versions
- ►diabetesjournals.org K Rave, S Bott, L Heinemann, S Sha, RHA … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—INH had a faster onset of action than both RHI and ILP, as indicated
by shorter time to early half-maximal effect (32 vs. 48 and 41 min,
respectively; P < 0.001 for IHN vs. RHI and P < 0.05 for IHN vs. ILP). Time ... Cited by 112 - Related articles - All 7 versions
- ►vcu.edu [PDF] SR Weiss, SL Cheng, IA Kourides, RA … - Archives of Internal Medicine, 2003 - Am Med Assoc Results At week 12, there was a significantly greater reduction in glycosylated
hemoglobin for the INH + OHA cohort (mean reduction, -2.3%) compared with the
OHA-only cohort (mean reduction, -0.1%, P<.001). Eleven patients (34%) ... Cited by 53 - Related articles - BL Direct - All 7 versions
JS Skyler, WT Cefalu, IA Kourides, WH … - The Lancet, 2001 - Elsevier 73 patients with type 1 diabetes mellitus were studied in an open-label,
proof-of-concept, parallel-group randomised trial. Patients in the experimental
group received preprandial inhaled insulin plus a bedtime subcutaneous ... Cited by 259 - Related articles - BL Direct - All 8 versions
- ►colfar.com [PDF] - Free from Publisher PA Hollander, L Blonde, R Rowe, AE Mehta, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS— HbA 1c decreased similarly in the inhaled (−0.7%) and subcutaneous
(−0.6%) insulin groups (adjusted treatment group difference: −0.07%, 95% CI
−0.32 to 0.17). HbA 1c <7.0% was achieved in more patients receiving ... Cited by 237 - Related articles - BL Direct - All 21 versions
- ►diabetesjournals.org RR Henry, SRD Mudaliar, WC Howland III, N … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Inhaled insulin showed area under the curve (AUC) (0–360 min) values
that were significantly greater for healthy subjects than for asthmatic subjects
(P = 0.013), whereas no difference was observed for maximum concentration ... Cited by 98 - Related articles - BL Direct - All 5 versions
